SEC filings and other documents

CARDAMYST launches as a first-in-class PSVT therapy, backed by strong data and financials.

CARDAMYST sees strong early adoption, payer traction, and plans for AFib trials and real-world data registry.

Early CARDEMYST launch shows strong uptake, broad prescriber base, and expanding payer coverage.

CARDAMYST launches as the first new PSVT therapy in decades, targeting broad adoption and expansion into AFib-RVR.

CARDAMYST launches as the first new PSVT therapy in decades, targeting rapid market adoption.

CARDAMYST launches with strong clinical data, broad provider targeting, and robust financial runway.

CARDAMYST launches for PSVT with rapid uptake, robust support, and plans for AFib expansion.

FDA-approved CARDAMYST targets rapid PSVT relief, unlocking a $1B+ market opportunity.

CARDAMYST launched with strong early demand and $200M in cash, supporting growth into 2027.

FDA approved Cardamyst for PSVT, enabling rapid, self-administered treatment with broad launch plans.

CARDAMYST aims to transform PSVT care with rapid, on-demand relief and strong commercial prospects.

Cash position strengthened and launch readiness heightened ahead of CARDAMYST FDA decision.

Etripamil aims for broad SVT market access with retail launch, affordable pricing, and payer support.

FDA acceptance of CARDAMYST response and new financing position the company for a potential 2025 launch.

CARDAMYST is poised for FDA resubmission and commercial launch, targeting major arrhythmia markets.

Q1 2025 net loss widened as Milestone focuses on FDA resolution for CARDAMYST approval.

Etripamil nears FDA approval for PSVT, targeting rapid, self-administered relief and broad market reach.

Mid-2025 launch planned for CARDAMYST, targeting high-value prescribers and broad payer access.

FDA decision on CARDAMYST pending; net loss narrows as launch and new trials approach.